Zanubrutinib Patent Expiration
Zanubrutinib is used for treating adult patients with various types of lymphomas and leukemias who have not responded to prior therapies. It was first introduced by Beigene Usa Inc
Zanubrutinib Patents
Given below is the list of patents protecting Zanubrutinib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Brukinsa | US10570139 | Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators | Apr 22, 2034 | Beigene |
| Brukinsa | US10927117 | Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof | Aug 15, 2037 | Beigene |
| Brukinsa | US11142528 | Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators | Apr 22, 2034 | Beigene |
| Brukinsa | US11591340 | Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof | Aug 15, 2037 | Beigene |
| Brukinsa | US11701357 | Treatment of B cell cancers using a combination comprising Btk inhibitors | Jun 24, 2039 | Beigene |
| Brukinsa | US11786531 | Methods of treating B-cell proliferative disorder | Jan 19, 2043 | Beigene |
| Brukinsa | US11851437 | Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof | Aug 15, 2037 | Beigene |
| Brukinsa | US11884674 | Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof | Aug 15, 2037 | Beigene |
| Brukinsa | US11896596 | Methods of treating B-cell proliferative disorder | Jan 19, 2043 | Beigene |
| Brukinsa | US11911386 | Methods of treating B-cell proliferative disorder | Jan 19, 2043 | Beigene |
| Brukinsa | US11970500 | Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)- 2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof | Aug 15, 2037 | Beigene |
| Brukinsa | US9447106 | Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators | Apr 22, 2034 | Beigene |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳